利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.019 秒)

    Platinum complexes and their use in therapy
    1.
    发明授权
    Platinum complexes and their use in therapy 失效
    铂复合物及其在治疗中的应用

    公开(公告)号：US07122668B2

    公开(公告)日：2006-10-17

    申请号：US10487154

    申请日：2002-08-21

    申请人： Yechezkel Barenholz ,  Dan Gibson ,  Yousef Najajreh ,  Elena Khazanov

    发明人： Yechezkel Barenholz ,  Dan Gibson ,  Yousef Najajreh ,  Elena Khazanov

    IPC分类号： C07F15/00 ,  A61K31/28

    CPC分类号： C07F15/0093

    摘要： The present invention concerns novel platinum complexes in which at least one of the amine ligand is a non-planar heterocyclic aliphatic amine. The platinum complexes may be in a trans or cis configuration and were found to posses therapeutic activites. Thus, the present concerns novel platinum complexes, pharmaceutical compositions comprising them and other uses thereof.

    摘要翻译： 本发明涉及其中至少一种胺配体是非平面杂环脂族胺的新型铂络合物。 铂络合物可以是反式或顺式构型，并被发现具有治疗活性。 因此，本发明涉及新颖的铂络合物，包含它们的药物组合物和其它用途。

    Combination Therapy
    3.
    发明申请
    Combination Therapy 审中-公开
    联合治疗

    公开(公告)号：US20080058274A1

    公开(公告)日：2008-03-06

    申请号：US11667671

    申请日：2005-11-15

    申请人： Yechezkel Barenholz ,  Elena Khazanov

    发明人： Yechezkel Barenholz ,  Elena Khazanov

    IPC分类号： A61K31/13 ,  A61K31/70 ,  A61P43/00

    CPC分类号： A61K9/1272 ,  A61K9/1273 ,  A61K9/1278 ,  A61K45/06

    摘要： The present invention concerns a new medical treatment involving the combination of two active entities, as well as pharmaceutical compositions comprising the two active entities. Specifically, the invention provides a pharmaceutical composition comprising a stable lipid assembly comprising as a first active entity an apoptosis-affecting lipid which does not self-aggregate in a polar environment to form liposomes and a lipopolymer. The pharmaceutical composition further comprises, as the second active entity, a cytotoxic amphipathic weak base drug carried by the lipid assembly or by a different liposome. According to one embodiment, the apoptotic-affecting lipid is a pro-apoptotic lipid. A preferred pro-apoptotic lipid is ceramide, preferably C6-ceramide. The cytotoxic amphipathic weak base drug is preferably doxorubicin or a biologically active, anthracyline-based doxorubicin analog thereof.

    摘要翻译： 本发明涉及涉及两种活性实体的组合的新药物治疗，以及包含两种活性物质的药物组合物。 具体地说，本发明提供一种药物组合物，其包含稳定的脂质组合物，其包含作为第一活性实体的细胞凋亡影响的脂质，其在极性环境中不自聚集以形成脂质体和脂质聚合物。 作为第二活性物质，药物组合物还包含由脂质组合或不同脂质体携带的细胞毒性两亲性弱碱性药物。 根据一个实施方案，凋亡影响脂质是促凋亡脂质。 优选的促凋亡脂质是神经酰胺，优选C6-神经酰胺。 细胞毒性两亲性弱碱药物优选为多柔比星或其生物活性的基于蒽环类的多柔比星类似物。

    Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
    4.
    发明申请
    Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer 审中-公开
    稳定的脂质体或胶束，其包含鞘氨醇和栓聚脂

    公开(公告)号：US20060198882A1

    公开(公告)日：2006-09-07

    申请号：US10551649

    申请日：2004-03-31

    申请人： Yechezkel Barenholz ,  Elena Khazanov ,  Joris Schillemans

    发明人： Yechezkel Barenholz ,  Elena Khazanov ,  Joris Schillemans

    IPC分类号： A61K39/395 ,  A61K9/127

    CPC分类号： A61K9/1272 ,  A61K9/1271

    摘要： The present invention concerns a stable lipid assembly comprising a biologically active lipid having a hydrophobic region and a polar headgroup, wherein the atomic mass ratio between the headgroup and hydrophobic region is less than 0.3, and a lipopolymer having a hydrophobic lipid region and a polymer headgroup, wherein the atomic mass ratio between the headgroup and hydrophobic region is at least 1.5 and optionally a lipid matrix composed of liposome forming lipids. Specific lipid assemblies according to the invention comprise the biologically active lipid, ceramide, a lipid derivatized with polyethylene glycol (lipopolymer) and optionally in combination with a phospholipid (e.g. Egg phosphatidylcholine (EPC) and hydrogenated soybean phosphatidylcholine (HSPC)). The lipid assemblies of the invention exhibited a therapeutic effect in vitro in tumor cells as well as in vivo in animal models and they deliver the biologically active lipid to the disease site.

    摘要翻译： 本发明涉及一种稳定的脂质组合物，其包含具有疏水区域和极性头基的生物活性脂质，其中头部基团和疏水区域之间的原子质量比小于0.3，并且具有疏水性脂质区域和聚合物头基 其中头部和疏水区域之间的原子质量比至少为1.5，并且任选地由形成脂质体的脂质组成的脂质基质。 根据本发明的特定脂质组合物包含生物活性脂质，神经酰胺，用聚乙二醇衍生的脂质（脂质聚合物），并且任选地与磷脂（例如卵磷脂酰胆碱（EPC）和氢化大豆磷脂酰胆碱（HSPC））组合。 本发明的脂质组合物在体外在肿瘤细胞中以及体内在动物模型中表现出治疗效果，并且将生物活性脂质递送至疾病部位。

    DEVICE, SYSTEM AND METHOD FOR IN-VIVO ANALYSIS
    6.
    发明申请
    DEVICE, SYSTEM AND METHOD FOR IN-VIVO ANALYSIS 审中-公开
    用于体内分析的装置，系统和方法

    公开(公告)号：US20110092768A1

    公开(公告)日：2011-04-21

    申请号：US12740764

    申请日：2008-11-02

    申请人： Noam Emanuel ,  Emil-Israel Katz ,  Elena Khazanov ,  Abraham Rubinstein ,  Yechezkel Barenholz ,  Abdel Kareem Azab

    发明人： Noam Emanuel ,  Emil-Israel Katz ,  Elena Khazanov ,  Abraham Rubinstein ,  Yechezkel Barenholz ,  Abdel Kareem Azab

    IPC分类号： A61B1/04 ,  B05D1/36 ,  B05D5/00

    CPC分类号： A61B1/041

    摘要： A device for in-vivo detection comprises a housing having an optical window and enclosing an imager that is configured to image the optical window. An external surface of the optical window has trypsin immobilized thereon, and may also be coated with a steric barrier protection, which may be polyethylene glycol (PEG). A trypsin-Alpha-1-antitrypsin complex formed on the window may have an affinity to a binding agent, which is tagged by a tag selected from a group consisting of a colorant, a fluorescent moiety, and a radioactive moiety.

    摘要翻译： 用于体内检测的装置包括具有光学窗口并且包围被配置成对光学窗口成像的成像器的壳体。 光学窗口的外表面具有固定在其上的胰蛋白酶，并且还可以涂覆有空间屏障保护，其可以是聚乙二醇（PEG）。 形成在窗户上的胰蛋白酶-β-1-抗胰蛋白酶复合物可以对结合剂具有亲和性，所述结合剂由选自着色剂，荧光部分和放射性部分的标签标记。